Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670790 | 0.88 | BRD4 (0.50) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1650294 | 0.88 | BRD4 (0.50) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL872959 | 0.83 | — | — | |
| SCHEMBL1650296 | 0.81 | BRD4 (0.44) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL16333538 | 0.80 | ALDH1A1 (0.41) | ALDH1A1KMT2A | |
| SCHEMBL17921259 | 0.78 | TLR4 (0.30) | — | |
| SCHEMBL11939930 | 0.77 | — | — | |
| SCHEMBL12688391 | 0.77 | — | — | |
| SCHEMBL12332449 | 0.77 | — | — | |
| SCHEMBL31072091 | 0.77 | BRD4 (0.41) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029377-B2 | Platelet-activating factor receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108595-A1 | PLATELET-ACTIVATING FACTOR RECEPTOR ANTAGONISTS | PTAFR, PAFAH1B2, PAFAH1B3 | BRD4 1323/4885CHRNB2 4479/4885CHRNA4 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.